Literature DB >> 25859992

QTc prolongation and treatment of multidrug-resistant tuberculosis.

E Harausz1, H Cox2, M Rich3, C D Mitnick4, P Zimetbaum5, J Furin1.   

Abstract

Electrocardiographic (ECG) monitoring is recommended for some of the new and re-purposed drugs used in the treatment of multidrug-resistant tuberculosis (MDR-TB), as these drugs have been shown to prolong the QTc interval. ECG monitoring is relatively new in the management of TB patients, and has several implications for programs and providers. This review discusses what is known about QTc prolongation and the medications currently being studied or used to treat MDR-TB, and discusses strategies for managing QTc prolongation in the context of treating such a serious infectious disease. It also reviews some major implications of ECG monitoring in the field, including interpretation of ECGs and QTc intervals, management of patients with prolonged QTc intervals, and contextualizing the risk of QTc prolongation for patients being treated for MDR-TB.

Entities:  

Mesh：

Year:  2015        PMID： 25859992     DOI： 10.5588/ijtld.14.0335

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  14 in total

1.  Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.

Authors:  Marc Weiner; Jon Gelfond; Teresa L Johnson-Pais; Melissa Engle; Charles A Peloquin; John L Johnson; Erin E Sizemore; William R Mac Kenzie
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.

Authors:  Fangchao Liu; Jingtao Gao; Mengqiu Gao; Yuhong Liu; Wei Shu; Li Xie; Yuxian Sun; Lijie Zhang; Liang Li; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2022-09-01       Impact factor: 5.938

3.  Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens.

Authors:  Tutik Kusmiati; Ni Made Mertaniasih; Johanes Nugroho Eko Putranto; Budi Suprapti; Nadya Luthfah; Soedarsono Soedarsono; Winariani Koesoemoprodjo; Aryani Prawita Sari
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-06-06

4.  Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases.

Authors:  Innocent Murhula Kashongwe; Fina Mawete; Nicole Anshambi; Nadine Maingowa; Murielle Aloni; Luc Lukaso L'osenga; Michel Kaswa; Zacharie Munogolo Kashongwe
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-09-22

5.  Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.

Authors:  Anthony J Garcia-Prats; Heather R Draper; Heather Finlayson; Jana Winckler; André Burger; Barend Fourie; Stephanie Thee; Anneke C Hesseling; H Simon Schaaf
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

6.  Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Authors:  Daniel L Clemens; Bai-Yu Lee; Aleidy Silva; Barbara Jane Dillon; Saša Masleša-Galić; Susana Nava; Xianting Ding; Chih-Ming Ho; Marcus A Horwitz
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

Review 7.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

Review 8.  Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis.

Authors:  Diana Machado; Miriam Girardini; Miguel Viveiros; Marco Pieroni
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640

Review 9.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12

Review 10.  Adolescent tuberculosis.

Authors:  Kathryn J Snow; Andrea T Cruz; James A Seddon; Rashida A Ferrand; Silvia S Chiang; Jennifer A Hughes; Beate Kampmann; Steve M Graham; Peter J Dodd; Rein M Houben; Justin T Denholm; Susan M Sawyer; Katharina Kranzer
Journal:  Lancet Child Adolesc Health       Date:  2019-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.